Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Rituximab + R-CHOP in DLBCL
NCT01054781Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jan 2009
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Samsung Medical Center. Primary endpoint: Complete Response Rate at 12 months. Started Jan 2009; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01054781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01054781.